Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biologics yield low rates of skin clearance in real-world psoriasis study

Key clinical point: Complete clearance rates with biologic therapies in real-world psoriasis studies may be lower than in clinical trials.

Major finding: At 6 and 12 months respectively, 23% and 26% of patients had achieved a PASI 100 score.

Study details: PSO-BIO-REAL (Plaque Psoriasis Treated With Biologics in a Real World Setting) is a multinational prospective trial that evaluated effectiveness of several biologic therapies in patients with moderate to severe plaque psoriasis.

Disclosures: The study was sponsored by Amgen/AstraZeneca; the manuscript was sponsored by LEO Pharma. One author was an AstraZeneca employee, two are LEO pharma employees, one author had no disclosures, and the remaining authors, disclosed serving as an adviser, paid speaker, consultant, and/or investigator for multiple companies.


Seneschal J et al. J Eur Acad Dermatol Venereol. 2020 May 4. doi: 10.1111/jdv.16568.